The Use of Acemannan in Alveolar Ridge Augmentation.
Not Applicable
Recruiting
- Conditions
- Patients with a residual alveolar ridge < 5 mm in the buccolingual direction (class 4 by Benic and Hammerle 2014) in the posterior mandible (molars and premolars area)..
- Registration Number
- IRCT20230609058431N1
- Lead Sponsor
- Damascus University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Patients aged 25-45 years old.
Patients with a residual alveolar ridge < 5mm in the buccolingual direction.
Patients with a residual alveolar ridge in one or more sites in the lower premolars and/or molars area.
Class I or II patients according to The American Society of Anesthesiologists (ASA)
Patients who understand, approve, and sign the informed consent statement.
Exclusion Criteria
Pregnant or nursing women.
2- Patients with a previous history of radiotherapy or chemotherapy to treat tumors in the head and neck region.
3- Patients with systemic disease that may affect normal healing.
4- Smokers.
5- patients with previous bone augmentation procedures in the same area.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The bone gain in the horizontal (buccolingual) direction clinically. Timepoint: Before intervention and 6 months after intervention. Method of measurement: The width of bone in the buccolingual direction will be measured clinically by a dental caliper.;The bone gain in the horizontal (buccolingual) direction radiologically. Timepoint: Before intervention and 6 months after intervention. Method of measurement: The width of bone in the buccolingual direction will be measured radiologically by CBCT.
- Secondary Outcome Measures
Name Time Method Histomorphometric analysis. Timepoint: 6 months after intervention. Method of measurement: A trephine will be used to get a bone core from the proposed implant site and for histological evaluation. After fixation and decalcification, the samples will be stained with hematoxylin and eosin (H&E), and bone formation, bone area percentage, and blood vessel formation will be evaluated.;Implants insertion torque. Timepoint: 6 months after intervention at the time of place implants. Method of measurement: Implants insertion torque will be measured by implant ratchet.;The implant stability quotient (ISQ). Timepoint: 6 months after intervention at the time of place implants. Method of measurement: The implant stability quotient (ISQ) will be measured by the Osstell device.